CareDx已最终确定一项针对实体器官移植分子检测的联邦医疗保险地方覆盖认定。此举标志着该公司在相关诊断服务领域的医保覆盖进程取得了关键进展,有望为其核心业务带来更明确的支付路径。
CareDx已最终确定一项针对实体器官移植分子检测的联邦医疗保险地方覆盖认定。此举标志着该公司在相关诊断服务领域的医保覆盖进程取得了关键进展,有望为其核心业务带来更明确的支付路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.